Ingaron lyophilisate for solution intramuscularly subcutaneous injection of 100 thousand. Me N5
Condition: New product
996 Items
More info
Description
Ingaron is a lyophilisate for preparing a solution for intramuscular and subcutaneous administration. The drug is a loose or porous mass of white. Hygroscopic.
Active ingredients
Release form
Pharmacological effect
Interferon gamma (immune interferon) is the most important pro-inflammatory cytokine, produced in the human body by natural killer cells, CD4 Th1 cells and CD8 cytotoxic suppressor cells. Interferon gamma receptors have macrophages, neutrophils, natural killer cells, cytotoxic T-lymphocytes. Interferon gamma: activates the effector functions of these cells, in particular their microbicidal activity, cytotoxicity, production of cytokines, superoxide and nitrooxide radicals, thereby causing the death of intracellular parasites, inhibits the B-cell response, interleukin-4, suppresses the production of IgE and the expression of the CD23 antigen, is an inducer of apoptosis of differentiated B cells, giving rise to autoreactive clones, cancels the suppressive effect of interleukin-4 on interleukin-2-dependent proliferation and the generation of lymphokine activated kills It activates the production of proteins of the acute phase of inflammation, enhances the expression of the C2 and C4 genes of the components of the complement system, unlike other interferons, increases the expression of GCGS antigens of both I and II classes on different cells, and induces the expression of these molecules even on those cells that do not express them constitutively. This increases the efficiency of the presentation of antigens and the ability of their recognition by T-lymphocytes, blocks the replication of viral DNA and RNA, the synthesis of viral proteins and the assembly of mature viral particles, has a cytotoxic effect on virus-infected cells, blocks the synthesis of β –TGF responsible for the development of pulmonary fibrosis and liver.
Indications
Treatment of chronic viral hepatitis C, chronic viral hepatitis B, HIV / AIDS infection and pulmonary tuberculosis in complex therapy. Prevention of infectious complications in patients with chronic granulomatous disease. Treatment of oncological diseases in complex therapy as an immunomodulator, including in combination with chemotherapy.Treatment of genital herpes virus infection and shingles (herpes zoster) in monotherapy. Treatment of urogenital chlamydia in complex therapy. Treatment of chronic prostatitis in complex therapy. Treatment of anogenital warts (human papillomavirus) and prevention of disease recurrence.
Dosage and administration
The introduction of the drug intramuscularly or subcutaneously. The contents of the vial are dissolved in 1-2 ml of water for injection. The dose of the drug is set individually. For the treatment of patients with chronic viral hepatitis B, chronic viral hepatitis C, as well as HIV / AIDS infection and pulmonary tuberculosis, the average daily dose for adults is 500,000 IU. It is entered once a day, every day or every other day. The course of treatment is from 1 to 6 months, if necessary, after 1-2 months, the treatment is repeated. For the prevention of infectious complications in patients with chronic granulomatous disease, the average daily dose for adults is usually 500,000 IU. It is entered once a day, every day or every other day. For a course of 5-15 injections, if necessary, the course is prolonged or repeated after 10-14 days. For the treatment of cancer, the average daily dose for adults is 500,000 IU. Introduced 1 time per day every other day. For the treatment of genital herpes virus infection, shingles (herpes zoster) and urogenital chlamydia, the average daily dose for adults is 500,000 IU. It is administered 1 time per day subcutaneously, every other day. The course of treatment is 5 injections. For the treatment of chronic prostatitis, the daily dose is 100,000 IU or 500,000 IU. It is administered 1 time per day subcutaneously, every other day. The course of treatment is 10 injections. For the treatment of anogenital warts, the daily dose is 100,000 IU. It is administered 1 time per day subcutaneously, after the conducted cryodestruction, every other day. The course of treatment is 5 injections.